1. Home
  2. ROIV vs GEHC Comparison

ROIV vs GEHC Comparison

Compare ROIV & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

N/A

Current Price

$35.43

Market Cap

28.7B

Sector

Health Care

ML Signal

N/A

Logo GE HealthCare Technologies Inc.

GEHC

GE HealthCare Technologies Inc.

N/A

Current Price

$65.73

Market Cap

29.1B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ROIV
GEHC
Founded
2014
1892
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
28.7B
29.1B
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
ROIV
GEHC
Price
$35.43
$65.73
Analyst Decision
Strong Buy
Buy
Analyst Count
13
21
Target Price
$48.08
★ $82.90
AVG Volume (30 Days)
★ 6.0M
3.3M
Earning Date
11-09-2026
10-28-2026
Dividend Yield
N/A
★ 0.25%
EPS Growth
N/A
★ 4.84
EPS
N/A
★ 0.85
Revenue
$8,260,000.00
★ $20,625,000,000.00
Revenue This Year
$530.75
$5.33
Revenue Next Year
$685.92
$4.60
P/E Ratio
★ N/A
$75.55
Revenue Growth
N/A
★ 4.84
52 Week Low
$15.99
$58.75
52 Week High
$42.50
$89.77

Technical Indicators

Market Signals
Indicator
ROIV
GEHC
Relative Strength Index (RSI) 43.66 47.88
Support Level $33.15 $60.14
Resistance Level $35.70 $66.04
Average True Range (ATR) 1.14 1.33
MACD -0.34 0.13
Stochastic Oscillator 35.90 60.90

Price Performance

Historical Comparison
ROIV
GEHC

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

About GEHC GE HealthCare Technologies Inc.

GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).

Share on Social Networks: